Clinical pharmacokinetics of etanercept: A fully humanized soluble recombinant tumor necrosis factor receptor fusion protein

Journal of Clinical Pharmacology

Volumn 45, Issue 5, 2005, Pages 490-497

  Zhou, Honghui ^a,b  

^a Clinical Pharmacology   (United States)

^b PFIZER INC   (United States)

Author keywords

Etanercept; Pharmacokinetics

Indexed keywords

DIGOXIN; ETANERCEPT; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; WARFARIN;

AGING; ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; BODY SIZE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MILK LEVEL; DRUG SYNOVIAL FLUID LEVEL; ETHNIC DIFFERENCE; HUMAN; INJECTION SITE; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY DYSFUNCTION; LACTATION; LIVER DYSFUNCTION; MAINTENANCE DRUG DOSE; MODEL; MONTE CARLO METHOD; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SIMULATION;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CHILD; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; MODELS, BIOLOGICAL; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; SPONDYLITIS, ANKYLOSING;

EID: 17644386569     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004273321     Document Type: Review

References (36)

1. Dower SK, Smith CA, Park LS. Human cytokine receptors. J Clin Immunol. 1990;10:289-299.
2. Silman AJ, Hochberg MC, eds. Epidemiology of the Rheumatic Diseases. New York: Oxford University Press; 1993.
3. Nanda S, Barthon J. Etanercept: a clinical review of current and emerging indications. Expert Opin Pharmacother. 2004;5:1175-1186.
4. Anandarajah AP, Ritchlin CT. Etanercept in psoriatic arthritis. Expert Opin Biol Ther. 2003;3:169-177.
5. Gorman JD, Sack KE, Davis JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. New Engl J Med 2002; 346:1349-1356.
6. Zhou H, Patat A, Parks V, Buckwalter M, Metzger D, Korth-Bradley J. Absence of a pharmacokinetic interaction between etanercept and warfarin. J Clin Pharmacol. 2004;44:543-550.
7. Korth-Bradley TM, Rubin AS, Hanna RK, Simcoe DK, Lebsack ME. The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother. 2000;34:161-164.
8. Lebsack ME, Hanna RK, Lange MA, Newman A, Ji W, Korth-Bradley JM. Absolute bioavailability of TNF receptor fusion protein following subcutaneous injection in healthy volunteers. Pharmacotherapy, 1997;17:1118.
9. Zhou H, Buckwalter M, Boni J, et al. Population-based pharmacokinetics of the soluble TNFr etanercept: a clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritis. Int J Clin Pharmacol Ther. 2004;42:267-276.
10. Kremer J, Spencer-Green G, Hanna R, Korth-Bradley J. Enbrel® (etanrecept) pharmacokinetics in patients with rheumatoid arthritis. Arthritis Rheum. 2000;43:S976.
11. Rowland M, Tozer TN, eds. Clinical Pharmacokinetics: Concepts and Applications. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 1995.
12. Keystone E, Schiff M, Kremer J, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50:353-363.
13. Yim DS, Zhou H, Buckwalter M, Nestorov I, Peck C, Lee H. Population pharmacokinetics analysis and simulation of time concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. J Clin Pharmacol. In press.
14. Nestorov I, DeVries T, Zitnik R. Pharmacokinetics of etanercept, a TNF antagonist, in patients with psoriasis treated in two double-blind phase 3 trials. J Am Acad Dermatol. 2004;50(Suppl): P148.
15. Lee H, Kimko H, Rogge M, Wang D, Nestorov I, Peck C. Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther. 2003;73:348-365.
16. Shammas FV, Dickstein K. Clinical pharmacokinetics in heart failure: an updated review. Clin Pharmacokinet. 1988;15:94-113.
17. Johnston D, Duffin D. Drug-patient interactions and their relevance in the treatment of heart failure. Am J Cardiol. 1992;70:109C-112C.
18. Soran O, Feldman A, Schneider V, Hanna R, Mann D, Korth-Bradley J. The pharmacokinetics of etanercept in patients with heart failure. Br J Clin Pharmacol. 2001;51:191-193.
19. Ostensen M, Eigenmann GO. Etanercept in breast milk. J Rheumatol. 2004;31:1017.
20. Zhou H, Parks V, Patat A, Le Coz F, Simcoe D, Korth-Bradley J. Absence of a clinically relevant interaction between etanercept and digoxin. J Clin Pharmacol. 2004;44:1244-1251.
21. Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet 2001;40:723-751.
22. HUMIRA (adalimumab), Physician Desk Reference, 2005. Abbott Laboratories; 2003.
23. Awni W, Cascella P, Oleka N, et al. Steady-state pharmacokinetics (PK) of adalimumab (HUMIRA™, Abbott) following 40 mg subcutaneous (sc) injection every other week (eow) in rheumatoid arthritis (RA) patients with and without methotrexate (MTX) background therapy. Arthritis Rheum. 2003;48(suppl):S140.
24. Velagapudi R, Noertersheuser P, Awni W, et al. Effect of methotrexate (MTX) coadministration on the pharmacokinetics (PK) of adalimumab (HUMIRA™, Abbott) following a single intravenous (iv) injection. Arthritis Rheum. 2003;48(suppl):S141.
25. Klareskog L, van der Heijde D, de Jager P, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis. Lancet. 2004;363:675-681.
26. Zhou H, Mayer P, Wajdula J, Fatenejad S. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. J Clin Pharmacol. 2004;44:1235-1243.
27. Harris ED Jr. Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med. 1990;322:1277-1289.
28. Arend WP, Dayer J-M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum. 1990;33:305-315.
29. Bendele AM, Chlipala ES, Scherrer J, et al. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum. 2000;43:2648-2659.
30. Feige U, Hu YL, Gasser J, Campagnuolo G, Munyakazi L, Bolon B. Anti-interleukin-1 and anti-tumor necrosis factor-α synergistically inhibit adjuvant arthritis in Lewis rats. Cell Mol Life Sci. 2000;57:1457-1470.
31. Genovese M, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 2004;50:1412-1419.
32. Suffredini AF, Fromm RE, Parker MM, et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med. 1989;321:280-287.
33. Suffredini AF, Reda D, Bank S, Tropea M, Agosti J, Miller R. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol. 1995;155:5038-5045.
34. Van der Poll T, Coyle S, Levi M, et al. Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory response to intravenous endotoxin in normal humans. Blood. 1997;89:3727-3734.
35. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology, preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727-735.
36. US Food and Drug Administration: Guidance for Industry: Clinical Development Programs for Drugs, Devices, and Biological Products for the Treatment of Rheumatoid Arthritis (RA). Rockville, Md: Center for Drug Evaluation and Research; 1999.